[
    {
        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "W3bkHC2cpiVGhP++NBsvHvoT2oxPuxwClvXMagZCiSOlsgzJV0o/fgNVSdstjazVxJhMRGD1Cm1DD+rkgdeMhK9q0LjDe2s4JoUTb6JVhII9l84JyBPfXX1z32Lum+oj3xOiDb+n+DzVI3d1TUzo5Iw2tsS5xMyLTrydGFR/2IE="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-07-03T14:54:35.900+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_769",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAwEAFJsLuzZ-2dMB67LDWGeCFsAEvposhL77ZKlWmQXY#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_769"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB09077"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "unituxin dinutuximab is indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy see clinical studies 14 unituxin is a gd2 binding monoclonal antibody indicated in combination with granulocyte macrophage colony stimulating factor gm csf interleukin 2 il 2 and 13 cis retinoic acid ra for the treatment of pediatric patients with high risk neuroblastoma who achieve at least a partial response to prior first line multiagent multimodality therapy 1"
                    }
                ],
                "https://w3id.org/biolink/vocab/association_type": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/TreatmentIndication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB09077",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]